4-Azaindole Derivatives M1 Muscarinic Receptor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cognitive deficits associated with neurological disorders like Alzheimer's disease and dementia with Lewy bodies face challenges due to non-selective activation of muscarinic acetylcholine receptors, leading to peripheral cholinergic side-effects, and the difficulty in obtaining selective M1 orthosteric ligands.
Innovation Solution
Development of 4-azaindole derivatives that act as positive allosteric modulators of the M1 muscarinic acetylcholine receptor, providing selective activation without the peripheral side-effects, thereby improving cognitive function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective muscarinic agonists are used to activate central cholinergic neurotransmission, then cognitive function is improved, but peripheral cholinergic side-effects occur due to activation of M2 and M3 receptors
Solution Approach 1:
The patent applies local quality by designing ligands with specific molecular characteristics (aromatic ring structures, hydrogen bond donors/acceptors, hydrophobic regions) that enable selective interaction with M1 receptor binding sites while avoiding M2 and M3 receptors. This structural specificity allows the compound to act locally on central cholinergic pathways without activating peripheral muscarinic receptors, thereby improving cognitive function without causing peripheral side-effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as aromatic ring substitution patterns, hydrogen bonding capacity, and hydrophobicity to optimize M1 receptor selectivity. By adjusting these chemical parameters, the ligands achieve enhanced affinity and selectivity for M1 receptors compared to non-selective agonists, resolving the contradiction between central efficacy and peripheral selectivity.
2Object-affected harmful factors
If selective M1 orthosteric ligands are developed, then peripheral side-effects are avoided, but the orthosteric binding site is highly conserved across muscarinic family making selectivity difficult to achieve
Solution Approach 1:
The patent applies local quality by introducing specific local molecular features (aromatic ring systems with particular substitution patterns, localized hydrogen bond donors and acceptors) that exploit subtle differences in the M1 orthosteric binding site environment. These localized structural characteristics enable selective binding to M1 while avoiding the highly conserved regions shared with M2 and M3 receptors, overcoming the challenge of orthosteric site conservation.
Solution Approach 2:
The patent uses parameter changes by systematically modifying ligand parameters such as aromatic ring substitution, hydrogen bonding strength, and molecular hydrophobicity to achieve M1 selectivity despite the conserved orthosteric site. These parameter optimizations allow the ligands to discriminate between muscarinic subtypes through subtle binding affinity differences, resolving the complexity of achieving selective ligand design.
3Reliability
If M1 selective ligands are used, then treatment effectiveness for cognitive impairment is improved, but drug development complexity increases due to the need for high selectivity
Solution Approach 1:
The patent applies local quality by defining specific molecular characteristics (aromatic ring structures, hydrogen bonding groups, hydrophobic regions) that collectively confer M1 selectivity. This structured approach to molecular design streamlines the drug development process by providing clear structural guidelines for achieving both effectiveness and selectivity, reducing overall development complexity despite the high selectivity requirements.
Solution Approach 2:
The patent employs parameter changes by establishing optimized ranges for molecular parameters (aromatic substitution patterns, hydrogen bond capacity, hydrophobicity) that simultaneously improve treatment effectiveness and simplify development. By identifying these optimal parameter ranges through systematic analysis, the patent reduces the complexity of developing M1-selective therapeutics while maintaining high treatment effectiveness.
Data Source
AI summary
4-Azaindole derivative as shown below or a pharmaceutically acceptable salt thereof which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition thereof as an active ingredient.